Switch theme
Sign up to access all valuation multiples
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
2024
161
LTM Revenue $0.1M
Last FY EBITDA $1.7B
$103M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Inhibrx Biosciences has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Inhibrx Biosciences achieved revenue of $0.2M and an EBITDA of $1.7B.
Inhibrx Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inhibrx Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $1.7B | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 851675% | XXX | XXX | XXX |
| EBIT | -$255M | XXX | -$331M | XXX | XXX | XXX |
| EBIT Margin | -255238% | XXX | -165724% | XXX | XXX | XXX |
| Net Profit | $754M | XXX | $1.7B | XXX | XXX | XXX |
| Net Margin | 755953% | XXX | 843786% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Inhibrx Biosciences's stock price is $15.
Inhibrx Biosciences has current market cap of $213M, and EV of $103M.
See Inhibrx Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $103M | $213M | XXX | XXX | XXX | XXX | $50.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Inhibrx Biosciences has market cap of $213M and EV of $103M.
Inhibrx Biosciences's trades at 513.7x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Inhibrx Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inhibrx Biosciences has a P/E ratio of 0.3x.
See valuation multiples for Inhibrx Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $213M | XXX | $213M | XXX | XXX | XXX |
| EV (current) | $103M | XXX | $103M | XXX | XXX | XXX |
| EV/Revenue | 1030.2x | XXX | 513.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 0.3x | XXX | 0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInhibrx Biosciences's last 12 month revenue growth is 986%
Inhibrx Biosciences's revenue per employee in the last FY averaged $1K, while opex per employee averaged $2.1M for the same period.
Inhibrx Biosciences's rule of 40 is -8289% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inhibrx Biosciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Inhibrx Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 986% | XXX | 229% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 851675% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -8289% | XXX | 852661% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 101871% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 165824% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inhibrx Biosciences acquired XXX companies to date.
Last acquisition by Inhibrx Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Inhibrx Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Inhibrx Biosciences founded? | Inhibrx Biosciences was founded in 2024. |
| Where is Inhibrx Biosciences headquartered? | Inhibrx Biosciences is headquartered in United States of America. |
| How many employees does Inhibrx Biosciences have? | As of today, Inhibrx Biosciences has 161 employees. |
| Who is the CEO of Inhibrx Biosciences? | Inhibrx Biosciences's CEO is Mr. Mark Paul Lappe. |
| Is Inhibrx Biosciences publicy listed? | Yes, Inhibrx Biosciences is a public company listed on NAS. |
| What is the stock symbol of Inhibrx Biosciences? | Inhibrx Biosciences trades under INBX ticker. |
| When did Inhibrx Biosciences go public? | Inhibrx Biosciences went public in 2024. |
| Who are competitors of Inhibrx Biosciences? | Similar companies to Inhibrx Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Inhibrx Biosciences? | Inhibrx Biosciences's current market cap is $213M |
| What is the current revenue of Inhibrx Biosciences? | Inhibrx Biosciences's last 12 months revenue is $0.1M. |
| What is the current revenue growth of Inhibrx Biosciences? | Inhibrx Biosciences revenue growth (NTM/LTM) is 986%. |
| What is the current EV/Revenue multiple of Inhibrx Biosciences? | Current revenue multiple of Inhibrx Biosciences is 1030.2x. |
| Is Inhibrx Biosciences profitable? | Yes, Inhibrx Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
